Comparative Analysis of Spouse’s Burden and Quality of Life in Major Depressive Disorder and Bipolar I Disorder

2019 ◽  
Vol 15 (3) ◽  
pp. 193-198
Author(s):  
Nayereh Maleki ◽  
Effat Sadeghian ◽  
Farshid Shamsaei ◽  
Lily Tapak ◽  
Ali Ghaleiha
Keyword(s):  
Quality Of Life ◽  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Negative Impact ◽  
Bipolar Disorders ◽  
Coping Skill ◽  
Major Depressive ◽  
Cross Sectional

Background: Spouses of patients with bipolar disorder may experience a different quality of life and burden than seen with major depressive disorder. Objective: This study was conducted to comparatively analyse spouse’s burden and quality of life in major depressive and bipolar disorders. Methods: This cross-sectional study was conducted on 220 spouses of patients with major depressive and bipolar disorders in the city of Hamadan in Iran, in 2018. Data collection tools included Zarit Burden and QOL-BREF questionnaires. Data were analyzed by a t-test using SPSS -16. Results: The findings showed that 11.8% of spouses of patients with depression and 85.5% of spouses of patients with bipolar disorder experienced severe burden (P < 0.001). The quality of life of spouses of patients with bipolar disorder was lower than with depressive disorder (P < 0.05). In both the groups, a negative correlation was found between burden and QOL. Conclusion: The spouses of patients with bipolar disorder experience more burden and lower quality of life than depression. In both the groups, burden has a negative impact on the quality of life. Professional help and supportive intervention can be provided to the spouses of patients with major depressive and bipolar I disorders to reduce their burden, strengthen their coping skill and thus improve their QOL.

scholarly journals 143 Effect of Tardive Dyskinesia on Quality of Life: Patient-Reported Symptom Severity Is Associated With Deficits in Physical, Mental, and Social Functioning

CNS Spectrums ◽  
2018 ◽  
Vol 23 (1) ◽  
pp. 89-89
Author(s):  
Joseph McEvoy ◽  
Benjamin Carroll ◽  
Sanjay Gandhi ◽  
Avery Rizio ◽  
Stephen Maher ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Tardive Dyskinesia ◽  
Social Withdrawal ◽  
Major Depressive ◽  
Health Burden ◽  
Pharmaceutical Industries

AbstractIntroductionTardive dyskinesia (TD), an often-irreversible movement disorder typically caused by exposure to antipsychotics, most commonly affects the face, mouth, and tongue and may be debilitatingObjectiveTo investigate TD burden on patients’ quality of life and functionalityMethodsAdults with clinician-confirmed schizophrenia, bipolar disorder, or major depressive disorder participated in an observational study. Approximately half (47%) ofparticipants had a clinician-confirmed TD diagnosis. Participants completed the SF-12v2 Health Survey® (SF-12v2), Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF), social withdrawal subscale of the Internalized Stigma of Mental Illness scale (SW-ISMI), and rated the severity of their TD symptoms. Group differences in SF-12v2 physical and mental component summaries (PCS and MCS), Q-LES-Q-SF, and SW-ISMI scores were analyzed.ResultsTD (n=79) and non-TD (n=90) groups were similar in age, gender, and number of patients with schizophrenia, bipolar disorder, and major depressive disorder. TD patients reported significantly worse scores on PCS (P=0.003), Q-LES-Q-SF (P<0.001) and SW-ISMI (P<0.001) than non-TD patients. The difference in PCS exceeded the established minimal clinically important difference (MCID) of 3 points. When stratified by TD severity, those with more severe symptoms had significantly worse Q-LES-Q-SF (P<0.001) and SW-ISMI (P=0.006) scores than those with less severe symptoms. Differences in PCS (P=0.12) and MCS (P=0.89) were in the expected direction and exceeded the MCID.ConclusionsAmong patients with psychiatric disorders, TD is associated with significant physical health burden and incremental mental health burden. TD severity is also associated with lower overall quality of life and greater social withdrawal.Presented at: Psych Congress; September 16–19, 2017; New Orleans, Louisiana, USA.Funding AcknowledgementsThis study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.

scholarly journals Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder

2019 ◽  
Vol Volume 15 ◽  
pp. 1649-1657 ◽  
Author(s):  
Qijing Bo ◽  
Lu Tian ◽  
Feng Li ◽  
Zhen Mao ◽  
Zhimin Wang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive

scholarly journals Internalized Stigma and Associated Factors among Patients with Major Depressive Disorder at the Outpatient Department of Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia, 2019: A Cross-Sectional Study

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Yadeta Alemayehu ◽  
Demeke Demilew ◽  
Getachew Asfaw ◽  
Henock Asfaw ◽  
Nigus Alemnew ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Addis Ababa ◽  
Cross Sectional Study ◽  
Internalized Stigma ◽  
Major Depressive ◽  
Cross Sectional ◽  
Specialized Hospital

Background. Internalized stigma has been found to be widespread among patients with major depressive disorder. When internalized stigma exists in patients with depression at a high level, it worsens the treatment outcome and quality of life. So the aim of the study is to assess the magnitude of internalized stigma and associated factors among outpatients with major depressive disorder at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Methods and Materials. An institutional-based cross-sectional study was conducted among 415 respondents from May 6 to June 13, 2019. Internalized stigma was assessed by using the internalized stigma of mental illness scale. Data was entered to Epi-data version 3.1 and analyzed using SPSS version 20. Bivariable and multivariable binary logistic analysis was done, and p values less than 0.05 were considered statistically significant with 95% CI. Results. The prevalence of high internalized stigma among patients with major depressive disorder was 33.5% (95% CI: 29.2, 38.3). Being single (AOR=2.54, 95% CI: 1.30, 4.95), having an illness greater than or equal to 2 years of duration (AOR=3.21, 95% CI: 1.66, 6.19), history of suicidal attempt (AOR=2.33, 95% CI: 1.35, 3.99), nonadherence to treatment (AOR=2.93, 95% CI: 1.62, 5.29), poor social support (AOR=4.72, 95% CI: 2.09, 10.64), and poor quality of life (AOR=3.16, 95% CI: 1.82, 5.49) were significantly associated with high internalized stigma at p value < 0.05. Conclusion. The magnitude of internalized stigma was high among patients with major depressive disorder. Reduction of internalized stigma through antistigma campaigns and supports given to patients at the earliest possible time is important to improve treatment outcome and quality of life and minimize suicidal behavior in patients with major depressive disorder.

scholarly journals Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia

2019 ◽  
Vol 28 (12) ◽  
pp. 3303-3312 ◽  
Author(s):  
Joseph McEvoy ◽  
Sanjay K. Gandhi ◽  
Avery A. Rizio ◽  
Stephen Maher ◽  
Mark Kosinski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Tardive Dyskinesia ◽  
Major Depressive

Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report

2021 ◽  
Author(s):  
Emma Morton ◽  
Venkat Bhat ◽  
Peter Giacobbe ◽  
Wendy Lou ◽  
Erin E. Michalak ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Repeated Measures ◽  
Short Form ◽  
Treatment Phase ◽  
Major Depressive ◽  
Symptomatic Remission ◽  
Substantial Degree

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.

Sign in / Sign up

Export Citation Format

Share Document